WO2016159576A3 - 1,2 나프토퀴논 유도체 및 이의 제조방법 - Google Patents

1,2 나프토퀴논 유도체 및 이의 제조방법 Download PDF

Info

Publication number
WO2016159576A3
WO2016159576A3 PCT/KR2016/003030 KR2016003030W WO2016159576A3 WO 2016159576 A3 WO2016159576 A3 WO 2016159576A3 KR 2016003030 W KR2016003030 W KR 2016003030W WO 2016159576 A3 WO2016159576 A3 WO 2016159576A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparing same
naphthoquinone derivative
pharmaceutically acceptable
naphthoquinone
derivative
Prior art date
Application number
PCT/KR2016/003030
Other languages
English (en)
French (fr)
Other versions
WO2016159576A2 (ko
Inventor
이휘성
이미정
김보정
이강우
노태철
서강식
김진환
민기남
Original Assignee
주식회사 케이티앤지생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 케이티앤지생명과학 filed Critical 주식회사 케이티앤지생명과학
Publication of WO2016159576A2 publication Critical patent/WO2016159576A2/ko
Publication of WO2016159576A3 publication Critical patent/WO2016159576A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 화학식 (1)로 표시되는 화합물, 그것의 약제학적으로 허용되는 염, 수화물, 용매화물, 프로드럭, 토토머(tautomer), 거울상 이성질체 또는 약학적으로 허용 가능한 부분입체 이성질체를 제공한다.
PCT/KR2016/003030 2015-03-27 2016-03-25 1,2 나프토퀴논 유도체 및 이의 제조방법 WO2016159576A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150043068 2015-03-27
KR10-2015-0043068 2015-03-27

Publications (2)

Publication Number Publication Date
WO2016159576A2 WO2016159576A2 (ko) 2016-10-06
WO2016159576A3 true WO2016159576A3 (ko) 2017-03-23

Family

ID=57007013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003030 WO2016159576A2 (ko) 2015-03-27 2016-03-25 1,2 나프토퀴논 유도체 및 이의 제조방법

Country Status (2)

Country Link
KR (2) KR102005068B1 (ko)
WO (1) WO2016159576A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190118118A (ko) 2018-04-09 2019-10-17 영진약품 주식회사 1,2-나프토퀴논 유도체 화합물을 포함하는 고형암 또는 혈액암의 예방 또는 치료용 약학 조성물
JP7007746B2 (ja) * 2018-04-09 2022-01-25 ヒュエン カンパニー リミテッド １，２－ナフトキノン誘導体化合物を含む固形癌または血液癌の予防または治療用薬学組成物
KR102201768B1 (ko) * 2019-02-28 2021-01-12 주식회사 엘마이토테라퓨틱스 벤조인다졸론 화합물 및 그 용도
KR102247694B1 (ko) * 2019-05-31 2021-05-03 주식회사 엘마이토테라퓨틱스 나프토퀴논 또는 벤조인다졸 화합물을 유효성분으로 포함하는 염증성 질환 치료용 약학적 조성물
JP2023007515A (ja) * 2019-12-10 2023-01-19 国立大学法人京都大学 発光材料、有機発光素子および化合物
EP4212530A1 (en) * 2020-08-17 2023-07-19 Lmito Therapeutics Inc. Imidazolquinoline or benzoindazolone compound and intermediate for preparing same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04330010A (ja) * 1991-02-21 1992-11-18 Sumitomo Pharmaceut Co Ltd 神経成長因子の産生または分泌促進剤
US5502214A (en) * 1993-07-19 1996-03-26 Dana Farber Cancer Institute 1,2-benzoquinones and methods for making and using same
KR20080099174A (ko) * 2007-05-07 2008-11-12 주식회사 머젠스 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
WO2012006104A2 (en) * 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
CN103022496A (zh) * 2012-12-28 2013-04-03 南开大学 一类锂二次电池用芳香稠环醌类化合物正极材料
EP2767532A1 (en) * 2012-12-21 2014-08-20 National Institute of Radiological Sciences Novel compound for imaging tau protein accumulated in the brain
KR20150080423A (ko) * 2013-12-30 2015-07-09 주식회사 케이티앤지생명과학 1,2 나프토퀴논 유도체 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4330010B2 (ja) * 2005-01-28 2009-09-09 パピエ・シー有限会社 鑑賞魚用水槽の冷却装置
KR20080047957A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 고혈압의 치료 및 예방을 위한 약제 조성물
US20100209513A1 (en) * 2007-10-11 2010-08-19 In Geun Jo Pharmaceutical composition containing micronized particles of naphthoquinone-based compound

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04330010A (ja) * 1991-02-21 1992-11-18 Sumitomo Pharmaceut Co Ltd 神経成長因子の産生または分泌促進剤
US5502214A (en) * 1993-07-19 1996-03-26 Dana Farber Cancer Institute 1,2-benzoquinones and methods for making and using same
KR20080099174A (ko) * 2007-05-07 2008-11-12 주식회사 머젠스 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
WO2012006104A2 (en) * 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
EP2767532A1 (en) * 2012-12-21 2014-08-20 National Institute of Radiological Sciences Novel compound for imaging tau protein accumulated in the brain
CN103022496A (zh) * 2012-12-28 2013-04-03 南开大学 一类锂二次电池用芳香稠环醌类化合物正极材料
KR20150080423A (ko) * 2013-12-30 2015-07-09 주식회사 케이티앤지생명과학 1,2 나프토퀴논 유도체 및 이의 제조방법

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN, J. ET AL.: "Design, Synthesis, and Characterization of New Embelin Derivatives as Potent Inhibitors of X-linked Inhibitor of Apoptosis Protein", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, no. 22, 2006, pages 5805 - 5808, XP027966089 *
DATABASE STN [O] 16 November 1984 (1984-11-16), retrieved from STN Database accession no. 16290-01-0 *
DATABASE STN [O] 16 November 1984 (1984-11-16), retrieved from STN Database accession no. 38982-08-0 *
DATABASE STN [O] 16 November 1984 (1984-11-16), retrieved from STN Database accession no. 4572-43-4 *
DATABASE STN [O] 16 November 1984 (1984-11-16), retrieved from STN Database accession no. 52112-43-3 *
KUBO, A. ET AL.: "Synthesis of Renierone, 7-methoxy-1,6-dimethyl-5,8-dihydroisoquinoline -5,8-dione and N-formyl-1,2-dydrorenierone, Antimicrobial Metabolites from a Marine Sponge, Reniera sp.", CHEM. PHARM. BULL., vol. 34, no. 10, 1986, pages 4056 - 4058 , 4061-4062, XP055373681 *
LUMIBAO, C. Y. ET AL.: "Electrochemical and Electrocatalytic Properties of Imidazole Analogues of the Redox Cofactor Pyrroloquinoline Quinone", ELECTROANALYSIS, vol. 20, no. 20, 2008, pages 2177 - 2184, XP055373686 *

Also Published As

Publication number Publication date
WO2016159576A2 (ko) 2016-10-06
KR102342250B1 (ko) 2021-12-23
KR102005068B1 (ko) 2019-07-30
KR20160116296A (ko) 2016-10-07
KR20180088627A (ko) 2018-08-06

Similar Documents

Publication Publication Date Title
WO2016159577A3 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
WO2016159576A3 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
EP3459925A4 (en) PROCESS FOR THE PREPARATION OF 2-HYDROXYL-4- (BENZYLOXY 2,3-DISUBSTITUTED) -5-SUBSTITUTED BENZALDEHYDE DERIVATIVE
WO2016011390A8 (en) Irak4 inhibiting agents
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
PH12016501517A1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MY194116A (en) Pharmaceutical compounds
EP3480198A4 (en) NEW COMPOUND OR ITS PHARMACEUTICALLY ACCEPTED SALT
WO2016205738A3 (en) Delivery systems for controlled drug release
EP3647310A4 (en) PROCESS FOR THE PREPARATION OF 2,5-FURANDIMETHYL CARBOXYLATE FROM HYDROXYMETHYL FURFURAL
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
WO2017042828A3 (en) Process for the preparation of selexipag
EP3786151A4 (en) METHOD FOR PRODUCING AN AMIDE COMPOUND
EP3617185A4 (en) METHOD FOR PREPARING AN AMIDE COMPOUND
PH12020500341A1 (en) Pentacyclic compound
WO2017168447A9 (en) A cyclic compounds and process for the preparation thereof
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
MX2019001228A (es) Metodo de produccion del compuesto de pirazol-amida.
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EP3733652A4 (en) PROCESS FOR THE PRODUCTION OF A THIOCARBOXAMIDINE SALT COMPOUND
WO2015111085A3 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
WO2016029216A3 (en) Method for producing amidine derivatives
WO2016042171A3 (en) A xanthene compound, and a colorant comprising the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16773357

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16773357

Country of ref document: EP

Kind code of ref document: A2